Tag - MESO


WB starts Mesoblast at OP; fair value estimate $8

William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...

Mesoblast Logo

Maxim ups Mesoblast to buy from hold; PT $18

Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...

Mesoblast Logo

Dawson James starts Mesoblast at buy; PT $14

Dawson James Securities initiated coverage of Mesoblast (NASDAQ:MESO; ASX:MSB) with a “buy” rating and $14 price target. The stock closed at $7.42 on Dec. 18. Mesoblast is using its proprietary technology platform to...